Skip to main content

Efficacy and safety of SGLT2 inhibitors in individuals with type 1 diabetes under continuous subcutaneous insulin infusion: a real-world study Cover

.blurhash-client-img { display: none !important; }

Efficacy and safety of SGLT2 inhibitors in individuals with type 1 diabetes under continuous subcutaneous insulin infusion: a real-world study

Endocrine Regulations

Volume 57 (2023): Issue 1 (January 2023)

By: Vania Benido Silva, Liliana Fonseca, Diana Borges Duarte, Francisca Marques Puga, Guilherme Assuncao, Susana Garrido, Sofia Teixeira, Joana Vilaverde and Maria Helena Cardoso

Open Access

|Aug 2023

Articles in this issue

DOI: https://doi.org/10.2478/enr-2023-0018 | Journal eISSN: 1336-0329 | Journal ISSN: 1210-0668

Journal RSS Feed

Language: English

Page range: 144 - 151

Published on: Aug 10, 2023

Published by: Slovak Academy of Sciences, Institute of Experimental Endocrinology

In partnership with: Paradigm Publishing Services

Publication frequency: 1 issue per year

Keywords:

continuous subcutaneous insulin infusion,

type 1 diabetes,

sodium-glucose co-transport 2 inhibitors,

diabetic ketoacidosis

Related subjects:

Molecular biology,

Basic medical science,

Basic medical science, other,

Clinical medicine,

Internal medicine,

Endocrinology, diabetology

© 2023 Vania Benido Silva, Liliana Fonseca, Diana Borges Duarte, Francisca Marques Puga, Guilherme Assuncao, Susana Garrido, Sofia Teixeira, Joana Vilaverde, Maria Helena Cardoso, published by Slovak Academy of Sciences, Institute of Experimental Endocrinology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Volume 57 (2023): Issue 1 (January 2023)

Previous article